EUDA Health expands skincare portfolio with advanced stem cell Secretome mask

EUDA Health Holdings (NASDAQ:EUDA) announced the expansion of its proprietary Helixé product portfolio with the commercial launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask.

The advanced skincare product was developed by Singaporean biotechnology company Chemokine, an entity for which EUDA holds exclusive global distribution rights.

The targeted product launch is designed to capitalize on the rapidly growing medical aesthetics and scientific skincare segments across the Asia-Pacific region.

EUDA plans to immediately leverage its established retail and distribution infrastructure in Malaysia and China to accelerate commercial sales and capture consumer market share within high-density regional demographics.

The Regenixé Mask utilizes induced pluripotent stem cell (iPSC)-derived skin stem cell secretome technology delivered via an advanced cellulose substrate.

The product formulation is explicitly engineered to support localized skin hydration, brightness enhancement, and cellular recovery.

Incorporating bio-cellular ingredients aligns with EUDA’s broader corporate positioning toward proactive longevity medicine and non-invasive personal health solutions.

The commercial rollout arrives amid broader structural growth within the global personal care ecosystem.

According to industry data from Mordor Intelligence, the global face mask market is projected to expand from approximately $7.95 billion in 2026 to $9.08 billion by 2031.

The Asia-Pacific territory remains a primary geographic driver of this expansion, supported by rising consumer discretionary income and an accelerating market demand for science-backed, premium skincare lines.